X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (42082) 42082
Book Review (9737) 9737
Publication (4049) 4049
Newspaper Article (550) 550
Newsletter (318) 318
Book Chapter (277) 277
Conference Proceeding (155) 155
Transcript (64) 64
Book / eBook (54) 54
Magazine Article (47) 47
Dissertation (46) 46
Web Resource (21) 21
Trade Publication Article (7) 7
Data Set (6) 6
Report (4) 4
Government Document (3) 3
Presentation (2) 2
Reference (2) 2
Streaming Video (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (35461) 35461
humans (29758) 29758
angiogenesis (26201) 26201
animals (16842) 16842
female (12716) 12716
oncology (12714) 12714
male (12242) 12242
angiogenesis inhibitors - therapeutic use (11711) 11711
cancer (11648) 11648
mice (9146) 9146
vascular endothelial growth factor (8267) 8267
endothelial growth-factor (7361) 7361
middle aged (6668) 6668
expression (6415) 6415
bevacizumab (6366) 6366
aged (6044) 6044
metastasis (5993) 5993
tumors (5956) 5956
apoptosis (5479) 5479
care and treatment (5296) 5296
research (5214) 5214
analysis (4788) 4788
cell line, tumor (4653) 4653
adult (4515) 4515
proteins (4505) 4505
angiogenesis inhibitors (4423) 4423
pharmacology & pharmacy (4379) 4379
treatment outcome (4243) 4243
chemotherapy (4230) 4230
cell biology (4190) 4190
health aspects (4049) 4049
ophthalmology (4020) 4020
vascular endothelial growth factor a - antagonists & inhibitors (3982) 3982
antineoplastic agents - therapeutic use (3838) 3838
gene expression (3801) 3801
therapy (3657) 3657
angiogenesis inhibitors - pharmacology (3626) 3626
neovascularization (3579) 3579
medicine (3575) 3575
vegf (3540) 3540
cells (3522) 3522
research article (3419) 3419
kinases (3347) 3347
neovascularization, pathologic - drug therapy (3327) 3327
signal transduction (3256) 3256
growth (3184) 3184
rodents (3151) 3151
rats (3059) 3059
in-vivo (2991) 2991
multidisciplinary sciences (2942) 2942
article (2846) 2846
inflammation (2842) 2842
vascular endothelial growth factor a - metabolism (2827) 2827
medicine & public health (2809) 2809
medicine, research & experimental (2809) 2809
biochemistry & molecular biology (2804) 2804
cancer therapies (2791) 2791
cell proliferation (2770) 2770
physiological aspects (2763) 2763
tumor angiogenesis (2723) 2723
inhibition (2706) 2706
angiogenesis inhibitors - administration & dosage (2705) 2705
cell proliferation - drug effects (2698) 2698
aged, 80 and over (2696) 2696
studies (2673) 2673
neoplasms - drug therapy (2641) 2641
development and progression (2610) 2610
science (2603) 2603
hypoxia (2599) 2599
endothelium (2595) 2595
disease models, animal (2523) 2523
in-vitro (2497) 2497
breast cancer (2484) 2484
endothelial cells (2347) 2347
antibodies, monoclonal - therapeutic use (2324) 2324
stem cells (2317) 2317
mice, nude (2315) 2315
antineoplastic combined chemotherapy protocols - therapeutic use (2299) 2299
cells, cultured (2235) 2235
biology (2220) 2220
antibodies, monoclonal, humanized (2216) 2216
activation (2201) 2201
antineoplastic agents - pharmacology (2181) 2181
surgery (2172) 2172
immunohistochemistry (2166) 2166
prognosis (2166) 2166
drug therapy (2145) 2145
genetic aspects (2142) 2142
medical research (2071) 2071
breast-cancer (2045) 2045
cell growth (2032) 2032
mice, inbred c57bl (2023) 2023
survival (1999) 1999
intravitreal injections (1998) 1998
macular degeneration (1989) 1989
angiogenesis inhibitors - adverse effects (1982) 1982
growth factors (1980) 1980
antibodies, monoclonal, humanized - therapeutic use (1971) 1971
abridged index medicus (1941) 1941
carcinoma (1899) 1899
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (22) 22
Gerstein Science - Stacks (18) 18
Collection Dvlpm't (Acquisitions) - Vendor file (5) 5
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Gerstein Science - Circulation Desk (1) 1
Gerstein Science - Missing (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UofT at Mississauga - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (42253) 42253
French (322) 322
German (187) 187
Japanese (128) 128
Chinese (107) 107
Spanish (98) 98
Polish (39) 39
Russian (31) 31
Portuguese (28) 28
Hungarian (26) 26
Czech (20) 20
Italian (20) 20
Romanian (18) 18
Dutch (14) 14
Danish (9) 9
Finnish (9) 9
Korean (9) 9
Hebrew (7) 7
Swedish (6) 6
Norwegian (5) 5
Croatian (3) 3
Icelandic (2) 2
Slovak (2) 2
Turkish (2) 2
Lithuanian (1) 1
Slovenian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 8, pp. 760 - 767
Purpose This international phase III trial (Investigating Torisel As Second-Line Therapy [INTORSECT]) compared the efficacy of temsirolimus (mammalian target... 
SURVIVAL | INTERFERON-ALPHA | EVEROLIMUS | ONCOLOGY | BEVACIZUMAB | DOUBLE-BLIND | AGENTS | Niacinamide - analogs & derivatives | TOR Serine-Threonine Kinases - metabolism | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | TOR Serine-Threonine Kinases - antagonists & inhibitors | Young Adult | Receptors, Vascular Endothelial Growth Factor - metabolism | Time Factors | Phenylurea Compounds - adverse effects | Treatment Failure | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Carcinoma, Renal Cell - enzymology | Female | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Kaplan-Meier Estimate | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Kidney Neoplasms - mortality | Disease Progression | Carcinoma, Renal Cell - mortality | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Renal Cell - secondary | Kidney Neoplasms - enzymology | Indoles - therapeutic use | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Index Medicus | ORIGINAL REPORTS
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 12/2011, Volume 10, Issue 12, pp. 2298 - 2308
Journal Article
Nature, ISSN 0028-0836, 04/2010, Volume 464, Issue 7291, pp. 1052 - 1057
The four receptors of the Notch family are widely expressed transmembrane proteins that function as key conduits through which mammalian cells communicate to... 
B-CELLS | ANTI-P185HER2 ANTIBODY | ANGIOGENESIS | MULTIDISCIPLINARY SCIENCES | REGULATORY REGION | MALIGNANT-MELANOMA | MUTATIONS | LEUKEMIA | GAMMA-SECRETASE | CANCER-THERAPY | INHIBITS TUMOR-GROWTH | Angiogenesis Inhibitors - immunology | Neoplasms - metabolism | NIH 3T3 Cells | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - pathology | Receptor, Notch2 - antagonists & inhibitors | Receptors, Notch - metabolism | Humans | Goblet Cells - drug effects | Receptors, Notch - genetics | Peptide Library | Receptors, Notch - antagonists & inhibitors | Antibody Specificity - immunology | Angiogenesis Inhibitors - therapeutic use | Antibodies - immunology | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - metabolism | Antibodies - therapeutic use | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Angiogenesis Inhibitors - pharmacology | Receptor, Notch1 - immunology | Neoplasms - blood supply | Receptor, Notch2 - immunology | Antibodies - adverse effects | Neoplasms - drug therapy | Antibodies - pharmacology | Animals | Signal Transduction - drug effects | Neovascularization, Pathologic - drug therapy | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Goblet Cells - pathology | Receptor, Notch1 - antagonists & inhibitors | Neoplasms - pathology | Receptors, Notch - immunology | Viral antibodies | Proteases | Proteolysis | Physiological aspects | Antibodies | Research | Properties | Membrane proteins | Cell growth | Cell cycle | Cancer | Crystal structure | Apoptosis | Receptors | Inhibitors | Toxicity | Notches | Mathematical models | Inhibition | Signalling | Diseases | Index Medicus
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, pp. CD007419 - CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular endothelial growth factor... 
CLINICAL-TRIAL | RANIBIZUMAB PLUS PROMPT | RANDOMIZED CONTROLLED-TRIAL | Receptors, Vascular Endothelial Growth Factor [therapeutic use] | DEFERRED LASER | MEDICINE, GENERAL & INTERNAL | PEGAPTANIB SODIUM | Bevacizumab [adverse effects; therapeutic use] | Laser Coagulation [methods] | Aptamers, Nucleotide [adverse effects; therapeutic use] | Network Meta-Analysis | QUALITY-OF-LIFE | Macular Edema [drug therapy; etiology; surgery] | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | Visual Acuity [drug effects; physiology] | COST-EFFECTIVENESS | Angiogenesis Inhibitors [adverse effects; therapeutic use] | LASER PHOTOCOAGULATION | Randomized Controlled Trials as Topic | Ranibizumab [adverse effects; therapeutic use] | Recombinant Fusion Proteins [adverse effects; therapeutic use] | Quality of Life | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | Triamcinolone [adverse effects; therapeutic use] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2015, Volume 33, Issue 2, pp. 172 - 179
Purpose This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma... 
ANGIOGENESIS | ONCOLOGY | PATHWAY | SUNITINIB | ABT-869 | RISK | BRIVANIB | INHIBITOR | CANCER | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Hand-Foot Syndrome - etiology | Indazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Liver Neoplasms - etiology | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Hypertension - chemically induced | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Liver Neoplasms - pathology | Carcinoma, Hepatocellular - etiology | Odds Ratio | Drug Administration Schedule | Risk Factors | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Niacinamide - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Phenylurea Compounds - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Sorafenib | Carcinoma, Hepatocellular - pathology | Aged | Indazoles - adverse effects | Indazoles - therapeutic use | Index Medicus | Bone3 | ORIGINAL REPORTS | Bios3
Journal Article
Nature, ISSN 0028-0836, 03/2015, Volume 519, Issue 7541, pp. 102 - 105
The BCR-ABL1 fusion gene is a driver oncogene in chronic myeloid leukaemia and 30-50% of cases of adult acute lymphoblastic leukaemia(1). Introduction of ABL1... 
MECHANISM | POSITIVE LEUKEMIA | TYROSINE KINASE | MULTIDISCIPLINARY SCIENCES | RESISTANCE | FOLLOW-UP | PATIENTS RECEIVING IMATINIB | KINASE INHIBITOR | BCR-ABL INHIBITOR | CHRONIC MYELOID-LEUKEMIA | T315I MUTANT | Proto-Oncogene Proteins c-abl - antagonists & inhibitors | Humans | Molecular Conformation | Imidazoles - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Crystallography, X-Ray | Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors | Protein Kinase Inhibitors - chemistry | Angiogenesis Inhibitors - therapeutic use | Imidazoles - therapeutic use | Phosphorylation - drug effects | Fusion Proteins, bcr-abl - chemistry | Cell Line | Proto-Oncogene Proteins c-abl - genetics | Indazoles - chemistry | Crystallization | Proto-Oncogene Proteins c-abl - chemistry | Angiogenesis Inhibitors - pharmacology | Models, Molecular | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Imidazoles - pharmacology | Drug Repositioning | Indazoles - pharmacology | Drug Resistance, Neoplasm - genetics | Fusion Proteins, bcr-abl - genetics | Vascular Endothelial Growth Factor Receptor-2 - chemistry | Protein Kinase Inhibitors - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Protein Binding | Proto-Oncogene Proteins c-abl - metabolism | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Kidney Neoplasms - drug therapy | Fusion Proteins, bcr-abl - metabolism | Indazoles - therapeutic use | Angiogenesis Inhibitors - chemistry | Drug Screening Assays, Antitumor | Axitinib | Genetic aspects | Research | Gene mutations | Drug resistance | Analysis | Phosphorylation | Inhibitor drugs | Leukemia | Bone marrow | Mutation | Kinases | Drug dosages | Patients | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9807, pp. 1931 - 1939
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2007, Volume 356, Issue 2, pp. 115 - 124
Sunitinib is one of several new antiangiogenic agents undergoing tests of efficacy in the treatment of various types of cancer. Renal-cell carcinoma of the... 
PHASE-III TRIAL | MEDICINE, GENERAL & INTERNAL | FUNCTIONAL ASSESSMENT | DOSE RECOMBINANT INTERLEUKIN-2 | CLINICAL-TRIALS | IN-VIVO | TUMOR-SUPPRESSOR GENE | TYROSINE KINASE INHIBITOR | RANDOMIZED-TRIAL | FACTOR RECEPTOR | ENDOTHELIAL GROWTH-FACTOR | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Pyrroles - adverse effects | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Female | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Receptors, Platelet-Derived Growth Factor - antagonists & inhibitors | Risk Factors | Interferon-alpha - therapeutic use | Kaplan-Meier Estimate | Kidney Neoplasms - mortality | Disease Progression | Carcinoma, Renal Cell - mortality | Indoles - adverse effects | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Renal Cell - secondary | Quality of Life | Indoles - therapeutic use | Kidney Neoplasms - pathology | Aged | Interferon-alpha - adverse effects | Kidney Neoplasms - drug therapy | Carcinoma, Renal cell | Comparative analysis | Drug therapy | Interferon alpha | Clinical trials | Interferon | Cytokines | Vascular endothelial growth factor | Skin cancer | Index Medicus | Abridged Index Medicus
Journal Article